These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
363 related articles for article (PubMed ID: 32085745)
1. Integrative analysis of breast cancer profiles in TCGA by TNBC subgrouping reveals novel microRNA-specific clusters, including miR-17-92a, distinguishing basal-like 1 and basal-like 2 TNBC subtypes. Kalecky K; Modisette R; Pena S; Cho YR; Taube J BMC Cancer; 2020 Feb; 20(1):141. PubMed ID: 32085745 [TBL] [Abstract][Full Text] [Related]
2. miRNA-135b Contributes to Uva P; Cossu-Rocca P; Loi F; Pira G; Murgia L; Orrù S; Floris M; Muroni MR; Sanges F; Carru C; Angius A; De Miglio MR Int J Med Sci; 2018; 15(6):536-548. PubMed ID: 29725243 [TBL] [Abstract][Full Text] [Related]
3. Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer. Liu YR; Jiang YZ; Xu XE; Yu KD; Jin X; Hu X; Zuo WJ; Hao S; Wu J; Liu GY; Di GH; Li DQ; He XH; Hu WG; Shao ZM Breast Cancer Res; 2016 Mar; 18(1):33. PubMed ID: 26975198 [TBL] [Abstract][Full Text] [Related]
4. miR-629-3p may serve as a novel biomarker and potential therapeutic target for lung metastases of triple-negative breast cancer. Wang J; Song C; Tang H; Zhang C; Tang J; Li X; Chen B; Xie X Breast Cancer Res; 2017 Jun; 19(1):72. PubMed ID: 28629464 [TBL] [Abstract][Full Text] [Related]
5. MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer. Ouyang M; Li Y; Ye S; Ma J; Lu L; Lv W; Chang G; Li X; Li Q; Wang S; Wang W PLoS One; 2014; 9(5):e96228. PubMed ID: 24788655 [TBL] [Abstract][Full Text] [Related]
6. Dysregulation of microRNA expression drives aberrant DNA hypermethylation in basal-like breast cancer. Sandhu R; Rivenbark AG; Mackler RM; Livasy CA; Coleman WB Int J Oncol; 2014 Feb; 44(2):563-72. PubMed ID: 24297604 [TBL] [Abstract][Full Text] [Related]
7. Comparing MicroRNA Profilings of Purified HER-2-Negative and HER-2-Positive Cells Validates miR-362-5p/Sema3A as Characteristic Molecular Change in Triple-Negative Breast Cancers. Zhang X; He Q; Sun L; Zhang Y; Qin S; Fan J; Wang J Dis Markers; 2019; 2019():6057280. PubMed ID: 31929841 [TBL] [Abstract][Full Text] [Related]
8. Identification of Specific miRNA Signature in Paired Sera and Tissue Samples of Indian Women with Triple Negative Breast Cancer. Thakur S; Grover RK; Gupta S; Yadav AK; Das BC PLoS One; 2016; 11(7):e0158946. PubMed ID: 27404381 [TBL] [Abstract][Full Text] [Related]
9. Small Non-Coding RNA Profiling Identifies miR-181a-5p as a Mediator of Estrogen Receptor Beta-Induced Inhibition of Cholesterol Biosynthesis in Triple-Negative Breast Cancer. Alexandrova E; Lamberti J; Saggese P; Pecoraro G; Memoli D; Cappa VM; Ravo M; Iorio R; Tarallo R; Rizzo F; Collina F; Cantile M; Bonito MD; Botti G; Nassa G; Weisz A; Giurato G Cells; 2020 Apr; 9(4):. PubMed ID: 32260128 [TBL] [Abstract][Full Text] [Related]
10. Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis. Bareche Y; Venet D; Ignatiadis M; Aftimos P; Piccart M; Rothe F; Sotiriou C Ann Oncol; 2018 Apr; 29(4):895-902. PubMed ID: 29365031 [TBL] [Abstract][Full Text] [Related]
11. Low prognostic implication of fibroblast growth factor family activation in triple-negative breast cancer subsets. Lee HJ; Seo AN; Park SY; Kim JY; Park JY; Yu JH; Ahn JH; Gong G Ann Surg Oncol; 2014 May; 21(5):1561-8. PubMed ID: 24385208 [TBL] [Abstract][Full Text] [Related]
12. MicroRNA-455-3p promotes invasion and migration in triple negative breast cancer by targeting tumor suppressor EI24. Li Z; Meng Q; Pan A; Wu X; Cui J; Wang Y; Li L Oncotarget; 2017 Mar; 8(12):19455-19466. PubMed ID: 28038450 [TBL] [Abstract][Full Text] [Related]
13. Differences in molecular features of triple-negative breast cancers based on the age at diagnosis. Gulbahce HE; Bernard PS; Weltzien EK; Factor RE; Kushi LH; Caan BJ; Sweeney C Cancer; 2018 Dec; 124(24):4676-4684. PubMed ID: 30311638 [TBL] [Abstract][Full Text] [Related]
14. microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers. Gasparini P; Cascione L; Fassan M; Lovat F; Guler G; Balci S; Irkkan C; Morrison C; Croce CM; Shapiro CL; Huebner K Oncotarget; 2014 Mar; 5(5):1174-84. PubMed ID: 24632568 [TBL] [Abstract][Full Text] [Related]
15. Integrative analysis of the inter-tumoral heterogeneity of triple-negative breast cancer. Chiu AM; Mitra M; Boymoushakian L; Coller HA Sci Rep; 2018 Aug; 8(1):11807. PubMed ID: 30087365 [TBL] [Abstract][Full Text] [Related]
16. Identification of Hub Genes to Regulate Breast Cancer Spinal Metastases by Bioinformatics Analyses. He Y; Cao Y; Wang X; Jisiguleng W; Tao M; Liu J; Wang F; Chao L; Wang W; Li P; Fu H; Xing W; Zhu Z; Huan Y; Yuan H Comput Math Methods Med; 2021; 2021():5548918. PubMed ID: 34055036 [TBL] [Abstract][Full Text] [Related]
17. Secreted breast tumor interstitial fluid microRNAs and their target genes are associated with triple-negative breast cancer, tumor grade, and immune infiltration. Terkelsen T; Russo F; Gromov P; Haakensen VD; Brunak S; Gromova I; Krogh A; Papaleo E Breast Cancer Res; 2020 Jun; 22(1):73. PubMed ID: 32605588 [TBL] [Abstract][Full Text] [Related]
18. microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression. Guo GC; Wang JX; Han ML; Zhang LP; Li L Cell Oncol (Dordr); 2017 Apr; 40(2):157-166. PubMed ID: 28054302 [TBL] [Abstract][Full Text] [Related]
19. Clinical Identification of Dysregulated Circulating microRNAs and Their Implication in Drug Response in Triple Negative Breast Cancer (TNBC) by Target Gene Network and Meta-Analysis. Qattan A; Al-Tweigeri T; Alkhayal W; Suleman K; Tulbah A; Amer S Genes (Basel); 2021 Apr; 12(4):. PubMed ID: 33918859 [TBL] [Abstract][Full Text] [Related]
20. A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients. Kleivi Sahlberg K; Bottai G; Naume B; Burwinkel B; Calin GA; Børresen-Dale AL; Santarpia L Clin Cancer Res; 2015 Mar; 21(5):1207-14. PubMed ID: 25547678 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]